Abstract

To observe the effect of roxadustat on blood pressure and micro-inflammatory response in patients with hemodialysis anemia and to provide a viable technique for the treatment of hemodialysis in anemia patients. A total of 100 hemodialysis anemia patients admitted to the nephrology department of our hospital from July 2020 to July 2021 were enrolled and randomly divided into an observation group (roxadustat) and a control group (human recombinant erythropoietin). The clinical efficacy, blood lipid metabolism, inflammatory factor levels, iron metabolism-related indicators, blood biochemical indicators, anemia indicators, adverse reactions and, blood pressure were recorded and compared. There was no significant difference in baseline data and serum indicators (p>0.05). The study group demonstrated superior performance to the control group in terms of clinical efficacy, blood lipid metabolism, inflammatory factor levels, iron metabolism-related indicators, blood biochemical indicators, anemia indicators, adverse reactions and blood pressure (p<0.05). Compared with human recombinant erythropoietin treatment, roxadustat exhibits a promising outcome in treating anemia and has slight impact on blood pressure of patients.